OSIMERTINIB for Squamous cell carcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 9 adverse event reports in the FDA FAERS database where OSIMERTINIB was used for Squamous cell carcinoma.

Most Reported Side Effects for OSIMERTINIB

Side Effect	Reports	%	Deaths	Hosp.
Death	10,423	37.6%	10,418	239
Malignant neoplasm progression	2,920	10.5%	574	354
Diarrhoea	1,408	5.1%	174	431
Drug resistance	1,026	3.7%	139	98
Fatigue	819	3.0%	102	231
Rash	772	2.8%	79	212
Decreased appetite	706	2.5%	138	273
Drug ineffective	627	2.3%	144	111
Dyspnoea	621	2.2%	158	327
Nausea	610	2.2%	82	228
Disease progression	607	2.2%	107	33
Off label use	576	2.1%	115	124
Interstitial lung disease	573	2.1%	221	305
Metastases to central nervous system	560	2.0%	125	109
Myelosuppression	510	1.8%	10	166